Doseology Sciences Inc. (DOSEF) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Doseology Sciences Inc. $0.10, price $0.11, upside -8.4%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Doseology Sciences Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
52‑month range $0.0516 – $1.02 · fair‑value band $0.0680 – $0.1360 · the $0.1114 price screens above the $0.1020 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Doseology Sciences in your weekly email
Every Wednesday you see whether Doseology Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures.
Show more
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Stock analysis
Doseology Sciences Inc. (DOSEF) currently trades at $0.1114, while our model-based Fair Value estimate is $0.1020, implying the stock looks roughly 9.2% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0680 (bear) to $0.1360 (bull), the price of $0.1114 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Doseology Sciences Inc. reported revenue of C$42.6K in FY2025 versus C$0 in FY2021. Reported net income was −C$448K in FY2025.
Key figures
Market cap $873K · EPS (TTM) $−0.1100 · Return on assets (EBIT) −38.7% · Free cash flow −$342K · Net cash $1.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 89% below its 52-week high and 116% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −8%, DOSEF screens richer than that median.
Fair Value models
Bear $0.0680Fair Value $0.1020Bull $0.1360
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−56.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.4%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11,277.5% (2022) → −1,108.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Doseology Sciences Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 6/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Above median
Fair Value upside−8% · Above median
Profitability
Return on assets0% · Above median
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Doseology Sciences Inc. Fair Value". https://www.fairvalue-calculator.com/stock/DOSEF
Frequently asked questions
Is Doseology Sciences Inc. (DOSEF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1020 versus the last price from Sep 18, 2026 of $0.1114, about −8% upside (fairly valued).
What is the fair value of DOSEF?
Our model-based fair value for Doseology Sciences Inc. is $0.1020 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.1114.
What is the quality score of DOSEF?
Doseology Sciences Inc. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Doseology Sciences Inc. (DOSEF)?
Our model-based price target is the fair value of $0.1020 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.0680, optimistic scenario $0.1360. It is a calculation from audited fundamentals, not an analyst target.
What is the Doseology Sciences Inc. stock forecast for 2026?
Our models put fair value at $0.1020, about −8% upside versus the last price from Sep 18, 2026 of $0.1114 (fairly valued). Cautious scenario $0.0680, optimistic scenario $0.1360. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Doseology Sciences Inc. (DOSEF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Doseology Sciences Inc. it is $0.1020 per share (as of Sep 23, 2026), against a price of $0.1114. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Doseology Sciences Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, DOSEF trades above its calculated fair value: price $0.1114, fair value $0.1020, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOSEF?
No. The price is what the market pays today ($0.1114); the fair value is what the company's own numbers justify ($0.1020). For Doseology Sciences Inc. the two are $0.0094 per share apart. That gap is exactly why we show both numbers side by side.
How much is Doseology Sciences Inc. worth?
The market values Doseology Sciences Inc. at about $873K (market capitalisation, as of Sep 23, 2026). Per share that is $0.1114; our models calculate a fair value of $0.1020 per share.
What do the bullish and bearish scenarios say about DOSEF?
Our models span a range for Doseology Sciences Inc.: cautious scenario $0.0680, base $0.1020, optimistic $0.1360 per share (as of Sep 23, 2026, price $0.1114). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is DOSEF from its 52-week high?
Doseology Sciences Inc. trades at $0.1114, about 89% below its 52-week high of $1.00 and 116% above the low of $0.0516 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1020 is for.
Which stocks are comparable to Doseology Sciences Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Doseology Sciences Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price $0.1114, calculated fair value $0.1020 (−8%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DOSEF calculated?
We run Doseology Sciences Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1020, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Doseology Sciences Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Doseology Sciences Inc. (DOSEF)?
The latest price we hold is from Sep 18, 2026 and stands at $0.1114. Our model-based fair value is $0.1020, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Doseology Sciences Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.0680 to $0.1360) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Doseology Sciences Inc.
How large is the market capitalisation of Doseology Sciences Inc. (DOSEF)?
The market capitalisation of Doseology Sciences Inc. is $873K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Doseology Sciences Inc. (DOSEF)?
Earnings per share at Doseology Sciences Inc. are $−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Doseology Sciences Inc. (DOSEF)?
On an EBIT basis the return on assets of Doseology Sciences Inc. is −38.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Doseology Sciences Inc. (DOSEF) generate?
The free cash flow of Doseology Sciences Inc. is −$342K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Doseology Sciences Inc. (DOSEF) hold?
Doseology Sciences Inc. holds more cash than debt, $1.3M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Doseology Sciences Inc. in the live analysis
One click puts Doseology Sciences Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026